PFM
HZNP

Privium Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Privium Fund Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$3.16M – 317
2022
Q1 		$3.16M Buy
+30,000
New +$2.92M 0.7% 28

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Privium Fund Management's HZNP Position: Q2 2022 in Review

Privium Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 30,000 shares — an estimated $3.16M sold.

Privium Fund Management first reported a position in HZNP in Q1 2022 and held it in 1 quarter. The position peaked at $3.16M in Q1 2022. 614 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

  • Privium Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Privium Fund Management sold 30,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $3.16M.
  • Privium Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • Privium Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.16M in Q1 2022.
  • 614 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Privium Fund Management's 13F filing for Q2 2022, filed 28 Jul 2022.